What smart money is saying about West Pharmaceutical Services
3 funds in our archive have pitched West Pharmaceutical Services — most recently Generation IM Global Equity Strategy in July 2026.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Get an email when a fund writes about it
Position history
Between Q2 2025 and Q3 2026, 6 fund letters reported a position in West Pharmaceutical Services — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 0 | 0 | 0 | 1 |
| Q2 2026 | 5 | 0 | 0 | 0 |
| Q1 2026 | 1 | 1 | 0 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
| Q2 2025 | 0 | 0 | 0 | 1 |
Fund activity · 6 positions · 1 move
- HoldsFindlay Park American FundJune 2026
“Beyond semiconductors, the contributor list was more varied. West Pharmaceutical Services and Waters benefited from accelerating organic revenue growth and improved guidance.”
West Pharmaceutical Services - June 2026
“West Pharmaceutical is a leading provider of injectable drug packaging solutions.”
West Pharmaceutical Services - June 2026
“Health care performance was more mixed, with a wide dispersion of outcomes within the portfolio. Argenx, West Pharmaceutical and Eli Lilly were among the strongest contributors, benefiting from company-specific profit cycles tied to differentiated therapies, improving demand visibility and solid execution.”
West Pharmaceutical Services - June 2026
“Away from the semiconductor space, West Pharmaceutical Services (+43%) also contributed positively, as shares responded to a strong first-quarter update and upgraded full-year guidance.”
West Pharmaceutical Services - June 2026
“Away from the semiconductor space, West Pharmaceutical Services (+43%) also contributed positively, as shares responded to a strong first-quarter update and upgraded full-year guidance.”
West Pharmaceutical Services - March 2026
“Valvoline, Inc. (VVV) is one of the fastest growing brands in the quick lube space, a corner of the market that continues to take share from general repair shops & dealerships. The 2023 sale of its global products business repositions Valvoline as a pure play. The past few years have been spent restructuring the business as a stand-alone entity. We see a double-digit top-line growth and margin expansion in FY26. Concerns over potential share losses to oral weight loss drugs and an unexpected CEO retirement announcement sent shares of West Pharmaceutical (WST) lower, offering an attractive entry point to a company we know well.”
West Pharmaceutical Services
Also mentioned · 1
These funds discuss West Pharmaceutical Services — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“The overreaction gave us an opportunity to buy at 12.5x expected fiscal 2026 EBITDA versus the company's historic 20x and its closest comparable, West Pharmaceutical (WST), at 22x to 25x.”
West Pharmaceutical Services
Fund coverage · 3 theses
- Generation IM Global Equity StrategyJuly 2026
West Pharmaceutical Services makes injectable-drug packaging components and is attractive for its entrenched market share, regulatory and biologics tailwinds, high margins, and strong management.
Read the full thesis - Upslope CapitalSeptember 2025
West Pharmaceutical Services is a leading producer of injectable drug delivery components, poised for continued growth due to advancements in drug development and reshoring trends, with a valuation that appears reasonable despite its historical premium.
Read the full thesis - Brasada CMJune 2025
West Pharmaceutical’s steep sell-off masks a fundamentally resilient business with irreplaceable components, long-term tailwinds in biologics and GLP-1s, and a compelling setup for patient investors.
Read the full thesis
Read every full thesis on West Pharmaceutical Services
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→